Effect of Exacerbations

The recovery rate of vision significantly faster in the group that received treatment with main interest MPIV were in patients whose visual acuity was 20/40 or less established at the outset. After six months there was no significant difference in visual acuity between the groups and the placebo MPIV. Oral prednisone given did not prove superior to placebo. It was surprising that during the month 6-24 follow-up, the risk of optic neuritis was higher repeated in both eyes were in patients treated with oral prednisone and MPIV by about 50 percent. Risk of outbreaks per cent of the new. Diagnosis of MS was the effect was greater in patients with higher risk of recurrence, ie, d. In those with brain lesions multiple MRI at baseline have led these results to the fact that it is not designed this study to evaluate the effect of sugary on exacerbations assessment later and there is no placebo group or protocol blinding for the group that received treatment by MPIV interpretation. Differences between the treatment groups was no longer significant after three years, which shows that the best MPIV slow the progression of MS, but without stopping.